AU2010213966B2 - Influenza hemagglutinin and neuraminidase variants - Google Patents

Influenza hemagglutinin and neuraminidase variants Download PDF

Info

Publication number
AU2010213966B2
AU2010213966B2 AU2010213966A AU2010213966A AU2010213966B2 AU 2010213966 B2 AU2010213966 B2 AU 2010213966B2 AU 2010213966 A AU2010213966 A AU 2010213966A AU 2010213966 A AU2010213966 A AU 2010213966A AU 2010213966 B2 AU2010213966 B2 AU 2010213966B2
Authority
AU
Australia
Prior art keywords
seq
residues
virus
sequences
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010213966A
Other languages
English (en)
Other versions
AU2010213966A1 (en
Inventor
Xing Cheng
Hong Jin
Kanta Subbarao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
National Institutes of Health NIH
Original Assignee
Government Of United States, Nat Institutes Of Health
MedImmune LLC
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of United States, Nat Institutes Of Health, MedImmune LLC, National Institutes of Health NIH filed Critical Government Of United States, Nat Institutes Of Health
Publication of AU2010213966A1 publication Critical patent/AU2010213966A1/en
Application granted granted Critical
Publication of AU2010213966B2 publication Critical patent/AU2010213966B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010213966A 2009-02-12 2010-02-03 Influenza hemagglutinin and neuraminidase variants Ceased AU2010213966B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15209409P 2009-02-12 2009-02-12
US61/152,094 2009-02-12
PCT/US2010/022970 WO2010093537A2 (en) 2009-02-12 2010-02-03 Influenza hemagglutinin and neuraminidase variants

Publications (2)

Publication Number Publication Date
AU2010213966A1 AU2010213966A1 (en) 2011-09-01
AU2010213966B2 true AU2010213966B2 (en) 2015-01-22

Family

ID=42562246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010213966A Ceased AU2010213966B2 (en) 2009-02-12 2010-02-03 Influenza hemagglutinin and neuraminidase variants

Country Status (11)

Country Link
US (2) US8613935B2 (enExample)
EP (1) EP2396033B1 (enExample)
JP (1) JP5818693B2 (enExample)
CN (1) CN102361649A (enExample)
AU (1) AU2010213966B2 (enExample)
BR (1) BRPI1008549A2 (enExample)
CA (1) CA2752205A1 (enExample)
MX (2) MX2011008497A (enExample)
RU (2) RU2535970C2 (enExample)
SG (2) SG173642A1 (enExample)
WO (1) WO2010093537A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0610525Y2 (ja) 1986-02-06 1994-03-16 三洋電機株式会社 キヤプスタンモ−タ制御回路
EP2902484A1 (en) 2004-05-25 2015-08-05 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
JP2010500034A (ja) 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
EP2396033B1 (en) 2009-02-12 2016-09-28 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
CA2811023A1 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
CN108103084B (zh) * 2017-11-21 2020-06-26 浙江迪福润丝生物科技有限公司 区分免疫和感染动物h5亚型禽流感疫苗株及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075955A1 (en) * 2002-03-13 2003-09-18 Lg Life Sciences Ltd. Method for enhancing immune responses by codelivering influenza np dna in dna immunization
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992522A (en) 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5665362A (en) 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
WO1993021306A1 (en) 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Genetically engineered attenuated viruses
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
WO1996010400A1 (en) 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
DE69634904T2 (de) 1995-10-31 2006-05-18 Dnavec Research Inc., Tsukuba Negativstrand rna virus mit selbständiger replikationsaktivität
CN1143892C (zh) 1995-11-01 2004-03-31 株式会社载体研究所 重组仙台病毒
US6090391A (en) 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
BR9712138A (pt) 1996-09-27 2000-01-18 American Cyanamid Co Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
ES2287977T3 (es) 1997-07-11 2007-12-16 Yale University Rabdovirus con cubiertas rediseñadas.
JP2001517448A (ja) 1997-09-19 2001-10-09 アメリカン・サイアナミド・カンパニー 弱毒化呼吸合胞体ウイルス
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
EP1035209A1 (en) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
EP1185615B1 (en) 1999-04-06 2007-08-01 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
RU2280690C2 (ru) 2000-03-02 2006-07-27 Полимун Сайнтифик Иммунбиологише Форшунг Гмбх Рекомбинантные вирусы гриппа а
PL205955B1 (pl) 2000-04-28 2010-06-30 St Jude Childrens Res Hospital Układ oparty na minimalnej liczbie plazmidów do wytwarzania infekcyjnych wirusów RNA o ujemnej nici, komórka gospodarza zawierająca taki układ, sposób wytwarzania wiriona wirusa RNA o ujemnej nici, sposób wytwarzania atenuowanego wirusa RNA o ujemnej nici, sposób wytwarzania zakaźnego wirusa o ujemnej nici do stosowania w szczepionkach i zastosowanie układu opartego na minimalnej liczbie plazmidów
ES2327103T3 (es) 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
USPP15035P3 (en) * 2001-06-27 2004-07-27 Marko Zaninovich, Inc. Grapevine ‘12-76-71’
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1499348B1 (en) * 2002-04-26 2014-10-01 MedImmune, LLC Method for producing infectious influenza b virus in cell culture
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
EP2902484A1 (en) 2004-05-25 2015-08-05 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
WO2006049061A1 (ja) 2004-11-01 2006-05-11 Eiken Kagaku Kabushiki Kaisha Ｈ５型又はｈ７型トリインフルエンザウイルスの検出方法
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
RU2315101C2 (ru) * 2006-01-10 2008-01-20 ГУ "Научно-исследовательский институт экспериментальной медицины "Российской Академии медицинских наук (ГУ НИИЭМ РАМН) Вакцинный штамм вируса гриппа а/17/калифорния/ 04/6 (н3n2) и донор аттенуации а/ленинград/134/17/к7/57 (н2n2) для его получения
JP2010500034A (ja) * 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
EP2396033B1 (en) 2009-02-12 2016-09-28 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075955A1 (en) * 2002-03-13 2003-09-18 Lg Life Sciences Ltd. Method for enhancing immune responses by codelivering influenza np dna in dna immunization
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use

Also Published As

Publication number Publication date
US9119812B2 (en) 2015-09-01
RU2535970C2 (ru) 2014-12-20
WO2010093537A2 (en) 2010-08-19
WO2010093537A3 (en) 2010-10-07
CN102361649A (zh) 2012-02-22
MX343411B (es) 2016-11-04
BRPI1008549A2 (pt) 2016-03-15
SG173642A1 (en) 2011-09-29
CA2752205A1 (en) 2010-08-19
SG2014010185A (en) 2014-06-27
US8613935B2 (en) 2013-12-24
JP5818693B2 (ja) 2015-11-18
JP2012517239A (ja) 2012-08-02
RU2014140731A (ru) 2016-04-27
MX2011008497A (es) 2011-12-16
US20140079726A1 (en) 2014-03-20
US20100330118A1 (en) 2010-12-30
AU2010213966A1 (en) 2011-09-01
EP2396033A2 (en) 2011-12-21
EP2396033B1 (en) 2016-09-28
EP2396033A4 (en) 2013-10-23
RU2011137404A (ru) 2013-03-20

Similar Documents

Publication Publication Date Title
EP2522719B1 (en) Influenza hemagglutinin and neuraminidase variants
EP2581093B1 (en) Influenza hemagglutinin and neuraminidase variants
AU2009268576B2 (en) Influenza hemagglutinin and neuraminidase variants
US8691239B2 (en) Influenza hemagglutinin and neuraminidase variants
US20120009215A1 (en) Influenza hemagglutinin and neuraminidase variants
US9119812B2 (en) Influenza hemagglutinin and neuraminidase variants
HK1171469A (en) Influenza hemagglutinin and neuraminidase variants
HK1184060A (en) Influenza hemagglutinin and neuraminidase variants

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired